• 1.jpg
  • 2.jpg
  • 4.jpg
  • 5.jpg
  • 6.jpg
  • 7.jpg
  • DSCF6103.jpg
  • DSCF6330.jpg
  • DSCF6361.jpg
  • DSCF6682.jpg
  • DSCF7352.jpg
  • DSCF7463.jpg
  • DSCF7655.jpg
  • DSCF7700.jpg
  • DSCF7758.jpg
  • DSCF7761.jpg
  • 8.jpg
  • 9.jpg


PRELIMINARY PROGRAMME & Second Call for Papers & Posters (December 2016)

Summit under the Auspieces of the Swiss Confederation

colab4

 

Conference Venue:

Messeplatz 21, 4058 Basel, Switzerland
Phone + 41 58 206 28 28 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Organizers Office:
European Foundation for Clinical Nanomedicine (CLINAM)
Alemannengasse 12, P.B. 4016 Basel, Switzerland
Phone +41 61 695 93 95 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Registration Office:
Organizers Schweiz GmbH, CLINAM SUMMIT 10/2017
Obere Egg 2, CH 4312 Magden, Switzerland
Phone +41 61 836 98 78 
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Scientific Committee

• Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (chairman)

• Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D)

• Prof. Dr. Lajos Balogh, American Society for Nanomedicine, Boston (USA) North Andover, Massachusetts, (USA)

• Prof .Dr. Gerd Binnig, Nobel Laureate, Munich (D)

• Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah MedicalSchool, Jerusalem (IL)

• Prof. Dr. med. Omid Farokhzad, Director, Center for Nanomedicine, Harvard Medical School and Brigham and Women's Hospital, Boston (USA)

• Prof. Dr. med. Dong Soo Lee, PhD. Chairman, Department of Nuclear Medicine Seoul National University (KOR)

• Dr. med. h.c. Beat Löffler, MA CLINAM-Foundation, Basel(CH)

• Prof. Dr. med. Marisa Papaluca Amati, European Medicines Agency, London(UK)

• Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL)

• Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)

Welcome to the European Global Summit for Nanomedicine and Targeted Medicine from May 7-10, 2017. The goal of the CLINAM Foundation is to contribute to the benefit of patients and society by exploring and translating leading edge technologies towards clinical application, with an emphasis on Nanomedicine, Targeted Medicine and Personalization. The summit keeps its tradition to build bridges from the enabling technologies to clinical application for major and neglected diseases. There is broad support for this summit by more than 35 collaborating initiatives.

Introduction

This is the 10th Summit of its kind. The CLINAM Foundation uses the opportunity of this Jubilee to present a programme with a strong focus on the route of nanomedicine from basic and enabling sciences to successful clinical applications in targeted and precision medicine and related fields, to discuss critically common bottlenecks based on the experience of the past decade by our broad international expert community. Over the past decade, the CLINAM Summit evolved to an exquisite and globally unique event that brings together all stakeholders in Nanomedicine and Targeted Medicine. It builds on the principle that fundamental scientists, developers and professionals in clinical application and in all to Nanomedicine related fields can
mutually learn from each other to find better solutions for the medicine of the future. Based on recent groundbreaking achievements, the next meeting in May will highlight


• The scientific basis of nanomedicine

• New developments in analytic and diagnostic technologies

• Targeting and personalization

• Improved understanding of the mechanisms of nano interacting with life

• Pitfalls of nano in medicine

• The impact of digital technologies and modeling on nanomedicine

• Experimental and clinical application digital technologies and modeling on nanomedicine

• Nanomedical Immunotherapies

• The pathway to safe nanomedicines, to enable breakthroughs in successful clinical applications

• The entrepreneurial pathways for Nanomedicine

• Plenary sessions will highlight the most recent and provocative developments. In addition

• Three Satellite Meetings are scheduled

CLINAM will welcome again more than 500 participants from the community of Nanomedicine and Targeted Medicine and aims at brings together the pioneers and worldwide opinion leaders, not only to learn and discuss but also to develop new ideas, create new collaborative projects and shape the future. Last year’s participating experts from 39 countries appreciate CLINAM Foundation’s role as the service provider for Nanomedicine and we will do everything necessary to surpass the expectation of the participants and to build a fruitful event that contributes to the important tasks in human healthcare that still await solutions.

First List of Speakers in CLINAM 10 / 17

Prof. Dr.med. Christoph Alexiou, Assistant Medical Director, Else Kröner‐Fresenius‐Foundation Professorship, Head Division Experimental Oncology and Nanomedicine, ENT‐Clinic, University Clinic, Erlangen (D) Dr. Elke Anklam, Director of the Health, Consumers and Reference Materials Directorate, Geel, (B) European Commission, DG Joint Research Centre and Measurement ISPRA) (I) Dr. Marianne Ashford PhD, Principal Scientist Drug Targeting, Pharmaceutical Development AstraZeneca, Macclesfield, Cheshire (UK); Prof. Dr. Lajos Balogh, American Society for Nanomedicine, Boston (USA) North Andover, Massachusetts, (USA) Prof. Dr. Yechezkel (Chezy) Barenholz ,Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem (IL) Patrick Boisseau, CEA‐Léti, EUNCL infrastructure coordinator, Chairman of the ETPN, Grenoble (F) Prof. Dr.Gerrit Borchard, Professor for Biopharmaceutical Sciences, President of the Swiss Society of Pharmaceutical Sciences, Vice President of the European Federation of PharmaceuticalSciences, Schoolof Pharmaceutical Sciences, Universities of Geneva and Lausanne (CH) Prof. Angela Brand, MD PhD MPH (USA), Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG), the Faculty of Health, Medicine and Life Sciences, Maastrich tUniversity, Maastricht (NL) Prof. Dr.Reto Brun, Swiss Tropical & PublicHealth Institute, Basel (CH) Dr. Werner Cautreels, CEO, Selecta Biosciences Watertown /Boston, MA (USA) Prof. Dr. Daan J.A. Crommelin, Emeritus Professor at the Department of Pharmaceutics, Utrecht, University (NL), Adjunct Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah (USA) Co‐founder of Octoplus, Leiden (NL) Prof. Dr.Paolo Decuzzi, Senior Researcher and Professor, Director of the Laboratoryof Nanotechnology for Precision Medicine, Italian Institute of Technology,Genova (I) Prof. Dr. Mike Eaton, Translation Advisory Board ENATRANS, Oxford, (UK) Prof. Dr. med. Omid Farokhzad, Associate Professor and Director, Center for Nanomedicine, Harvard Medical School, Brigham, and Women's Hospital, Boston (USA) Prof. Dr.Xavier Fernàndez Busquets, PhD, Nano-malaria Joint Unit, Associate, InstituteforBioengineering of Catalonia, Barcelona,Member of the Barcelona Centre for International Health Research, Barcelona (E) Robert E. Geertsma, M.Sc., Senior Scientist, Centre for Health Protection RIVM - National Institute for Public Health and the Environment, Bilthoven (NL) Dr. Gregor Haefliger, Head of National Research and Innovation Division, State Secretariat for Education, Research and Innovation SERI, Bern (CH) Dr. Michael Hehenberger, Ph.D., HM NanoMed, Westport CT (USA) Prof. Dr. med. Patrick Hunziker, President of the International Society for Nanomedicine, Basel (CH) Dr. Piotr Grodzinski, Ph.D., Director, NCI Allience for Nano-technology in Cancer, Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, MD (USA) Prof. Dr. med. Keon W. Kang, MD, PhD, Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul (KR) (tbc) Dr. med. Ingrid Klingmann, PhD, Chairman, European Forum for Good Clinical Practice (EFGCP) Wezembeek‐Oppem (B) Dr.Silke Krol, Principal Investigator and Head of Nanomedicine lab, IRCCS, Istituto Oncologico"Giovanni Paolo II", Bari (I) and Fondazione IRCCS Istituto Neurologico"Carlo Besta", Milano (I) Dr. med. Tony Lahoutte, PhD., Head of the Nuclear Medicine Department, University Hospital Brussels and principal investigator at in Vivo Cellular and Molecular Imaging, vrije Universiteit Brussel, (B) Prof. Dr. Twan Lammers, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) and Department of Targeted Therapeutics, University of Twente, Enschede (NL) Prof. Dr.med. Dong Soo Lee, PhD. ,Chairman of the Departmentof Nuclear Medicine Seoul National University Seoul (KOR) Prof. Dr. Jean-Marie Lehn, Nobel Laureate, Laboratory of Supramolecular Chemistry ISIS, University of Strasbourg (F) Prof. Dr. Didier Letourneur, Director of Cardiovascular Bioengineering, Laboratory for Translational Vascular Science, INSERM, Paris (F) Dr. med. h.c. Beat Löffler, CEO, European Foundation for Clinical Nanomedicine, Basel (CH) Dr.Bernd Riebesehl, Principal Fellow,Novartis Pharma AG, Basel (CH) Prof. Prof.Dr.med. Harald Mangge, interim Head Clinical Institute for Medical and Chemical Laboratory Diagnosis (CIMCL) Medical University of Graz, Graz (A) Prof. Dr. med. Volker Mailänder, Center for Translational Nanomedicine, Universitätsmedizin der Johannes-Gutenberg Universität Mainz (D) Prof. Dr. Pascal Mäser, Head, Parasite Chemotherapy, Swiss Tropical & Public Health Institute, Basel (CH) Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute, Vice President, Leidos Biomedical Research, Inc., Frederick, (USA) Prof. Dr. Heinz Mehlhorn, Heinrich-Heine-Universität Düsseldorf, Düsseldorf (D) Prof. Dr.Debabrata Mukhopadhyay, Professor of Biochemistryand Molecular Biology, AssociateDirector of the Mayo Clinic Comprehensive Cancer Center, Mayo Clinic College of Medicine, AssociateDirector of the Tumor Microenvironment and Nanomedicineprograms and AssociateDirector of Mayo Clinic Comprehensive Cancer Center for Global Alliances, Mayo Clinic College of Medicine, Rochester,MN. (USA) Prof.Dr. Willem Mulder, Associate Professor of Radiology at Icahn School of Medicineat Mount Sinai,NY, (USA), Professor of Radiology, ISMMS Professor of Cardiovascular Nano-medicine,  Director, Nanomedicine Program, AMC, Amsterdam (NL) Prof. Dr. Bert Müller,Thomas Straumann‐Chair for Materials Science inMedicine, University Basel (CH) Prof. Dr. André Nel, M.B. Ch.B., Ph.D.,Division Chief, Nanomedicine, Professor, Medicine, Director and PI, NSF/EPA-funded Center for Environmental Implications of Nanotechnology, California NanoSystems Institute Member, California NanoSystems Institute, Los Angeles, CA (USA) Prof. Dr. med. Yasuhiro Matsumura M.D. PhD, Director, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital, Kashiwa City, Japan Dr. Sitaramaiah Mokkapati, President Indian Nanomedicine Society, Former Deputy Director‐General in the Divisionof Reproductive Health and Nutrition, Headquarters, Indian Council of MedicalResearch, New Delhi (IN) (tbc) Prof. Dr. Guangjun Nie, Professor of Nanobiology and Medicine, National Center for Nanoscience and Technology, China, Beijing (CHN) Prof. Dr. Andrew Owen PhD FRSB FBPhS, Professor of Pharmacology, Molecular and Clinical Pharmacology University of Liverpool (UK) Prof. Dr.med. Marisa Papaluca, Senior Scientific Advisor, Human Medicines Research Development Support Division, London (UK) Prof. Dr.Wolfgang J. Parak, Department of Physics, Philipps University of Marburg, Marburg (D) and CIC Biomagune, San Sebastian (ES) Dr. Anil Patri, Chair, Nanotechnology Task Force, Director, NCTR-ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, National Center for Toxicological Research (NCTR), Jefferson, Arkansas USA) Prof. Dr. Adriele Prina-Mello, PhD Ussher Assistant Professor, Trinity Translational Medicine Institute (TTMI), Department of Clinical Medicine, School of Medicine and AMBER / CRANN, Trinity College Dublin, the University of Dublin (IRL) Dr. Cristianne JF Rijcken, PharmD PhD, Founder and CSO, Crystal Delivery, Maastricht (NL) Prof. Dr. EderLilia Romero, Programa de Nanomedicinas, Universidad Nacionalde Quilmes, Buenos Aires (AR) (tbc) Dr.Kumiko Sakai‐Kato, Section Head, Divisionof Drugs, National Institute of Health Sciences (NIHS), Ministryof Health, Labour and Welfare (MHLW), Tokyo (J) (tbc) Prof. Dr. Kirsten Sandvig, Centre for Cancer Biomedicine, Institute for Cancer Research, the Norwegian Radium Hospital, Oslo, University Hospital and University of Oslo, Oslo (N) Prof. Dr.Giacinto Scoles, Department of Medical and Biological Sciences, University Hospital, Universityof Udine, Udine (I) and Biology Department, Temple University, Philadelphia, PA (USA) Hripsime Shahbazian, MSc, Senior Science Advisor, Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa (CND)Prof. Dr. med. Raymond Schiffelers, Professor of Nanomedicine, Clinical Chemistry and Haematology, University Medical Center Utrecht UMCU, Utrecht (NL) Dr. Tore Skotland, Centre for Cancer Biomedicine, Institute for Cancer Research, Oslo University (N) Dr. Sc. Nat. Ruth Schmid,Vice President Marketing, SINTEF Materials and Chemistry, Biotechnology and Nanomedicine, Polymer Particles and Surface Chemistry, Trondheim (N) Prof. Dr. Avi Schroeder, PhD, Assistant Professor of Chemical Engineering Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies Technion - Israel Institute of Technology, Haifa (IL) Dr.Scott Steele,Ph.D., Director,Government and Academic Research Alliances ,Associate Professor, Public Health Sciences University of Rochester (USA) Prof. Dr.Gert Storm, Department Pharmaceutics, Utrecht Institute for PharmaceuticalSciences (UIPS), Utrechtand Division Imaging, University Medical Center Utrechtand Targeted Therapeutics, MIRA Institutefor Biomedical technology and Technical Medicine, University of Twente (NL) Prof. Dr. med. Janos Szebeni, Head of the Nanomedicine Research and Education Center, Semmelweis University, Budapest (H) Dr. Andreas Wagner, Head Liposome Technology, Polymun Scientific, Immunbiologische Forschung GmbH, Klosterneuburg (A) Dr. med. Frank Weichold, Ph. D. , Director of CriticalPath and Regulatory Science Initiatives, Officeof Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of theCommissioner Food and Drug Administration (FDA), Silver Spring, MD (USA) Prof. Dr.Wolfgang Wenzel, Research Leader Nanoscale and BimolecularSimulation, Karlsruhe Instituteof Technology (KIT), Karlsruhe (D) Dr.MarieluiseWippermann, CEO, TecoMedical Ltd, Sissach(CH) Dr. Joy Wolfram, Department of Nanomedicine, The Methodist HospitalResearch Institute, Houston, (USA) & CASKey Laboratory for BiomedicalEffects of Nanomaterials & Nanosafety, National Centerfor Nanoscience & Technologyof China,Beijing (CHN) Prof. Dr. Ada Yonath, Nobel Laureate, Weizmann Institute of Science - Structural Biology Department Rehovot, (IL) Prof. Dr. Yuliang Zhao, PhD, Professor in Chemistry, Deputy Director-General, National Center for Nanoscience and Technology, China, Director, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety,  Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing (CHN). Further speakers will be announced in the second Preliminary Programme. (February 15)

 

DOWNLOAD THE PRELIMINARE PROGRAMME

 

The CLINAM Foundation is able to realize this annual Summit due to many sponsors and the foundation is very grateful for the opportunity to gather so many excellent experts to advance the field of Nanomedicine.

The 10th CLINAM-Summit is held 2017 under the Auspices of the Swiss Confederation and has as one of the principal goals, to broaden the frontiers of knowledge of Nanomedicine in Diagnosis, Therapy and Treatment and make innovation happen by novel drugs and devices and new ways of development and cooperation.

We look forward, to welcome all Stakeholders in Nanomedicine and Targeted Medicine in Basel to debate together, to investigate together, to learn from each other and to come to novel findings and together advance the discipline to the benefit of the patient and humankind.

 

 


 The Foundation

The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.

Nanotechnology for Medicine

Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.